Tapestry Initiates Phase 2 Trial Of TPI 287 For The Treatment Of Advanced Pancreatic Cancer

October 04th, 2007 | Category: Cancer

Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. that is the second Phase 2 trial exploring the activity of TPI

287 in various tumor types: the first Phase 2 trial began earlier that year in advanced hormone refractory prostate cancer. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • EntreMed Commences Phase 2 Study With MKC-1 In Pancreatic Cancer
  • AmpliMed Corporation Announces Start Of Randomized Phase 2 Trial Of Amplimexon In Pancreatic Cancer
  • Proteolix Initiates Phase 2 Clinical Trial Of Carfilzomib In Patients With Relapsed Solid Tumors
  • Oncothyreon Initiates Phase 1b Trial Of PX-12 In Patients With Advanced Metastatic Cancer
  • Positive Glufosfamide Results From A Phase 2 Clinical Trial Presented At European Cancer Conference (ECCO)

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.